CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]
Revenue	$ 3,424,000	$ 3,414,000
Costs and expenses:
Patient expenses	1,341,000	1,467,000
Selling, general and administrative	1,289,000	1,259,000
Loss on derecognition of gamma knife and related assets	663,000	0
Total	3,293,000	2,726,000
Operating income	131,000	688,000
Interest expense	(113,000)	(153,000)
Interest income	112,000	7,000
Loss from investments in unconsolidated entities, net	(743,000)	(101,000)
(Loss) income before income taxes	(613,000)	441,000
Income tax benefit	192,000	97,000
Net (loss) income	$ (421,000)	$ 538,000
Basic and diluted net (loss) income per share (in dollars per share)	$ (0.05)	$ 0.07
Weighted average common shares outstanding (in shares)	7,792,185	7,792,185